Navigation Links
LegalView Reports That Skin Cancer Drug May Offer Treatment to Mesothelioma Patients
Date:12/11/2008

LegalView recently discovered that scientists in Australian were using a skin cancer cream on mesothelioma-infected mice to determine if the cream could provide any benefits to mesothelioma patients. In a majority of the mice, scientists found the cream "curing" the mesothelioma patients.

Denver, CO (PRWEB) December 11, 2008 -- LegalView, the number one legal resource available on the Web, recently reported on its mesothelioma information blog of a scientific discovery that may offer varied levels of relief to mesothelioma cancer patients. Several Australian scientists used a skin cancer cream treatment known as Imiquimod combined with an additional cancer treatment known as antiCD40 to treat mesothelioma tumor patients. Nearly 50 percent of the mice tested in the study showed positive results, although treatment side effects were found to be severe.

Mesothelioma is a rare form of cancer that is caused by the exposure and inhalation of asbestos fibers and dust. Unfortunately, many individuals are at risk for the development of the cancer even those who were not employed in occupations where asbestos was readily available at high exposure levels. Asbestos was used in several products as well as during the construction of homes, apartments, hospitals, schools and office/government buildings until its use was banned in the 1970s and 1980s when mesothelioma cancer and the dangers of asbestos began to surface.

Individuals who suffer from mesothelioma cancer or believe they may have the beginnings of mesothelioma cancer should seek medical attention immediately. Additionally, receiving a free legal consultation from an experienced mesothelioma lawyer may assist in the development of any potential mesothelioma lawsuits that occur. Such litigation may be able to result in monetary compensation for a victim to pay for mesothelioma treatments. To learn more visit the LegalView mesothelioma information portal at http://mesothelioma.legalview.com/.

LegalView also offers a multitude of additional information on more than 100 legal topics ranging from the latest information on traumatic brain injuries to recent controversial pharmaceutical topics such as the Ketek liver damage scare or the Baxter Heparin recall.

Traumatic brain injury (TBI) affects approximately 5.4 million Americans, with an increasing number of victims deriving from veterans returning from the war in Iraq. TBI can have a devastating impact on not only the victim, but also on family, friends and co-workers of a TBI patient. Additionally, when an individual avoids or denies treatment for their brain injury symptoms their condition will likely worsen and cause dramatic negative impact on their life as well as others around them. Patients who feel they may have suffered from a traumatic brain injury should seek medical attention immediately.

Both Ketek and Heparin have repeatedly made headlines for their dangerous side effects that have been investigated by the U.S. Food and Drug Administration (FDA). Ketek is an antibiotic used to treat upper respiratory infections such as community acquired pneumonia or bronchitis. It was released from Sanofi-Aventis in 2004 and, after only two years on the market, investigations regarding the drug's side effects begin. Ketek has been allegedly linked to the development of liver failure/disease in more than 100 individuals, according to an FDA health alert. Individuals who have taken the prescription medication and feel they may be suffering from liver-related conditions should speak with a medical professional as well as consult a pharmaceutical attorney in case a potential Ketek class action lawsuit becomes necessary.

Baxter's Heparin is a blood thinner that is administered to patients undergoing major surgery including heart damage or kidney failure. The drug has been used in the United States since the 1930s and is often imported from Chinese manufacturers. In 2007, several hundred reports of allergic reactions began flooding in the offices of the FDA regarding the administration of Heparin, according to the FDA. The company has since halted sale of the drug, but those who may be affected by the Baxter Heparin dangers should receive medical assistance as well as speak to a qualified pharmaceutical lawyer for additional assistance.

About LegalView:
LegalView.com is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of LegalView.com's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at www.LegalView.com.

###

Read the full story at http://www.prweb.com/releases/2008/12/prweb1734334.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. LegalView Reveals Details of the FDA Mandated Black Box Warning For Fluoroquinolone Antibiotics Such as Cipro and Levaquin
2. LegalView Unveils Details of a Breakthrough Mesothelioma Cancer Early Detection Test for Mesothelioma Patients
3. LegalView Brain Injury Site Reports Department of Veteran Affairs Request for Research on TBI and Soldiers
4. LegalView Highlights Top Brain Injury Rehabilitation Hospitals in the United States - 5.3 Million Americans Suffer from TBI
5. LegalView Reports Details of War Veteran Brain Injuries Overlooked By Officials for Years
6. LegalView Warns Proton Pump Inhibitor Patients of Potential Bone Fracture Risk Associated with Drug
7. LegalView Re-launching Truck Accident Injury Information Portal with Updated News and Information on the Costly and Dangerous Accidents
8. LegalView Reports Cancer Risk for St. Louis Residents After Unapproved Asbestos Removal During Demolition
9. LegalView Informs Patients of Possible Cimzia Cancer Link, Drug Commonly Used to Treat Arthritis
10. LegalView Reintroduces its Medical Malpractice Information Portal with Updated Links to Finding Immediate Legal Assistance
11. LegalView Re-Launches its Avandia Information Portal with News of the Type 2 Diabetes Drug's Risks and Dangers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may be commonplace ... injury, it occurs when the muscles around the pelvis become inflamed. Over time, ... lower torso, as well as accompanying tenderness and weakness. Without proper intervention, it ...
(Date:3/27/2017)... , ... March 27, 2017 , ... ... simulation -centric training, today announced the launch of a new research study, The ... the skills needed to execute that strategy, and the actual success of achieving ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... announce that for a second year in a row; they are the recipient ... designers in the industry voted on the award at Design Connections 2017. Top ...
(Date:3/27/2017)... CA (PRWEB) , ... March 27, 2017 , ... Janet Schloz is still in shock ... the best days I’ve had in a long time,” she said. , She thinks the ... of money that I never thought I would have to help my students.” , The ...
(Date:3/27/2017)... ... ... The Anaheim Hills office accelerates and supports FNCC’s growth and further strengthens ... professionals over the past 6 months and is continuing to recruit new talent with ... of 2017. , “This new office is a direct result of our strong ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... DUBLIN and BOSTON ... AGN), a leading global pharmaceutical company and Paratek ... on the development and commercialization of innovative therapies ... Phase 3 trials of sarecycline for the treatment ... week primary efficacy endpoints. Sarecycline is a once-daily, ...
(Date:3/27/2017)... Texas , March 27, 2017   Genprex, Inc. , ... that Julien Pham , MD, the Company,s Chief Operating Officer, ... investor conferences. Sachs 5th Annual Cancer BioPartnering & ... New York, NY ... BioCentury 24th Annual Future Leaders in ...
(Date:3/24/2017)... PUNE, India , March 24, 2017 ... Stimulators Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," the spine bone stimulators ... $724 million by 2022, growing at a CAGR of 3.6% during the forecast ... ... Allied Market Research Logo ...
Breaking Medicine Technology: